A5045444077- Multiple Myeloma Research and Treatments
- SARS-CoV-2 and COVID-19 Research
- Peptidase Inhibition and Analysis
- Immunotherapy and Immune Responses
- Monoclonal and Polyclonal Antibodies Research
- Protein Degradation and Inhibitors
- Animal Virus Infections Studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Mechanisms and Therapy
- Chronic Lymphocytic Leukemia Research
- Platelet Disorders and Treatments
- Synthesis and Biological Activity
- Cytokine Signaling Pathways and Interactions
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Chemokine receptors and signaling
- Lung Cancer Treatments and Mutations
- Diverse Scientific Research Studies
- Cancer therapeutics and mechanisms
- Synthesis and Biological Evaluation
Institute for Myeloma & Bone Cancer Research
2021-2024
Oncotherapeutics (United States)
2024
University of California, Los Angeles
2023
Patients with multiple myeloma have unpredictable responses to vaccination for COVID-19. Anti-spike antibody levels can determine which patients develop antibodies at similar healthy controls, and are a known correlate of protection.A patient developed protective anti-spike after (608 IU/mL), but nonetheless severe breakthrough COVID-19 just 10 weeks following his second mRNA-1273.Sequencing the viral isolate revealed an extensively mutated variant spike protein mutations, including E484Q...
Multiple myeloma (MM) patients with smoldering (S) disease are defined by a lack of CRAB/SLiM criteria but may transform into requiring treatment. The International Myeloma Working Group risk stratification model for SMM uses serum M-protein, serum-free light chain ratio, and bone marrow plasma cell percentage. We investigated whether baseline B-cell maturation antigen (sBCMA) levels predictive progression among 65 SMM. A receiver operating characteristic curve was used to establish...
We have reported that IgG antibody responses following two mRNA COVID-19 vaccinations are impaired among patients with multiple myeloma (MM). In the current study, sixty-seven MM were tested for anti-spike antibodies 0-60 days prior to their first vaccination, 14-28 second dose, and both before after third dose of mRNA-1273 or BNT162b2 vaccines. After doses, most patients' (93 %) levels declined ineffective (<250 BAU/mL) (D3). D3 elicited in 84 % (61 full response 22 partial response). The...
Abstract Background Multiple myeloma (MM) patients have variable responses to mRNA vaccination COVID‐19. Little is known regarding their vaccine‐induced antibody levels over time. Methods We monitored spike IgG 24 weeks among a subset of 18 MM who showed full response after two vaccinations. Results had more rapid decline in as compared eight healthy controls, with power law half‐lives 72 days (vs. 107 days) and exponential 37 51 days). The longer SARS‐CoV‐2 were likely undetectable...
Isatuximab is approved for treatment of relapsed/refractory multiple myeloma (RRMM) with dexamethasone and carfilzomib or pomalidomide. Patients receiving these three-drug regimens have exhibited more Grade ≥ 3 adverse events (AEs) compared to the two-drug class combination isatuximab steroids alone. Thus, this single-center retrospective study investigated efficacy methylprednisolone (ISAdm) RRMM patients showing only biochemical progression (BP) their disease.Twenty-four exhibiting BP were...
Multiple myeloma (MM) is an incurable bone marrow (BM)-based cancer involving clonal plasma cells. Most patients show elevated levels of serum monoclonal protein (sMP) and kappa or lambda free light chains (sFLCs) at diagnosis. However, around 1-2% patients, termed nonsecretory, do not produce these biomarkers. As the disease progresses, more may become unevaluable using conventional markers, requiring invasive expensive procedures like BM biopsies positron emission tomography-computed...
Abstract Objectives Data regarding bone marrow (BM) sampling and cytogenetic testing rates for identification of translocation (11q13;14q32) their changes over time in a multiple myeloma (MM) population are limited. We analyzed these metrics at clinic specializing the treatment MM. Methods A total 760 BM aspirate samples from 351 patients were collected between August 2004 October 2021. statistics, frequency, incidence t(11;14) single Results report that most (54.4%) had only 1 collected;...